Goldman Sachs’s Axsome Therapeutics AXSM Stock Holding History

Goldman Sachs’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-35,400	Closed	-$2.82M	–	5556
2023 Q4	$2.82M	Hold	35,400	–	–	﹤0.01%	3648
2023 Q3	$2.47M	Buy	+35,400	New	+$2.65M	﹤0.01%	3602
2023 Q1	–	Sell	-20,200	Closed	-$1.56M	–	5911
2022 Q4	$1.56M	Buy	+20,200	New	+$1.21M	﹤0.01%	4121
2021 Q1	–	Sell	-20,000	Closed	-$1.63M	–	6072
2020 Q4	$1.63M	Buy	+20,000	New	+$1.5M	﹤0.01%	3870
2020 Q2	–	Sell	-7,200	Closed	-$424K	–	5195
2020 Q1	$424K	Buy	+7,200	New	+$587K	﹤0.01%	4304

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs's AXSM Position: Q2 2026 in Review

Goldman Sachs reduced its Axsome Therapeutics (AXSM) stake by 46% in Q2 2026, selling an estimated $41.6M and leaving 229,668 shares worth $56.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1701.

Goldman Sachs first reported a position in AXSM in Q4 2015 and has held it in 35 quarters since. The position peaked at $71.2M in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Goldman Sachs held 229,668 shares of Axsome Therapeutics worth $56.2M as of Q2 2026.
Goldman Sachs sold 191,779 Axsome Therapeutics shares in Q2 2026, an estimated $41.6M.
Axsome Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1701 holding.
Goldman Sachs first reported a position in Axsome Therapeutics in Q4 2015 and has held it in 35 quarters since.
Goldman Sachs's Axsome Therapeutics position peaked at $71.2M in Q1 2026.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.